Product

General Description

FDG-F18 is a radiopharmaceutical compound used in PET (Positron Emission Tomography) imaging. As a glucose analog labeled with the radioactive isotope Fluorine-18, it enables the identification of areas with increased metabolic activity—a specific characteristic of cancer cells.

It is considered the gold standard for the diagnosis and monitoring of oncological, neurological, and cardiovascular diseases.

FDG - F18
ABOUT THE PRODUCT

Technical Properties

FDG-F18 is a radiopharmaceutical with an optimal half-life for PET imaging, administered intravenously as a sterile solution. The product is delivered under controlled conditions, in compliance with GMP standards and radiation protection regulations.

  • Active Ingredient: Fluorodeoxyglucose labeled with radioactive Fluorine-18
  • Emission Type: Positron (β⁺)
  • F-18 Half-life: ~110 minutes
  • Administration Form: Injectable solution, intravenous
  • Packaging: Sterile vials in shielded containers
  • Storage: Controlled temperature and radiation protection conditions
Request an Offer

Medical Use

  • Diagnosis and staging in oncology
  • Monitoring the effectiveness of cancer treatment
  • Assessment of neurological disorders (Alzheimer's, epilepsy)
  • Investigation of ischemic heart diseases

Beneficii clinice

  • Accurate visualization of metabolic activity
  • Identification of primary lesions and metastases
  • Development of personalized treatment strategies
  • Comparative evaluation before and after treatment

Safety and Regulations

  • Manufactured in a GMP-certified facility
  • Approved and regulated by CNCAN
  • Delivered through a rapid and secure distribution system (ADR)

Delivery and Logistics

  • Delivery Time: Daily deliveries as scheduled, under isothermal conditions with radiation protection
  • Coverage Area: Regional and national distribution
  • Support: Personalized logistics guide for partner clinics

We’d be happy to meet you

Leave us your details and we’ll get in touch with you.

Contact
flag

RO